Literature DB >> 23912631

Elevated expression of coactivator-associated arginine methyltransferase 1 is associated with early hepatocarcinogenesis.

Shigehiro Osada1, Shugo Suzuki, Chiaki Yoshimi, Miho Matsumoto, Tomoyuki Shirai, Satoru Takahashi, Masayoshi Imagawa.   

Abstract

Aberrant expression of regulators for epigenetics is involved in tumorigenesis. There is an urgent need to identify and characterize regulators concerned with epigenetics in the early stages of hepatocarcinogenesis. In the present study, we found that the expression of coactivator-associated arginine methyltransferase 1 (CARM1), a histone methyltransferase that functions as a cofactor for nuclear hormone receptors and several transcription factors, was elevated in adenomas and aberrant in carcinomas during hepatocellular carcinogenesis. In addition to RNA expression, immunohistochemical staining of liver sections revealed that CARM1 was highly expressed in the nucleus of tumor marker glutathione S-transferase placental form (GST-P)-positive foci. Neoplastic transformation of GST-P-positive foci guides the formation of hepatocellular carcinomas. CARM1 expression was not elevated in GST-P-negative regions. Furthermore, a luciferase reporter analysis revealed that CARM1 activated the Gst-p promoter in H4IIE, a hepatocellular carcinoma cell line. This activation was mediated by the enhancer element responsible for the carcinogenic-specific expression of Gst-p and nuclear factor E2-related factor 2. Knockdown of Carm1 by shRNA in H4IIE cells inhibited cell proliferation. These findings suggest that aberrantly expressed CARM1 in tumor marker-positive cells promotes tumorigenesis in the early stages of hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23912631     DOI: 10.3892/or.2013.2651

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  15 in total

1.  Transition state mimics are valuable mechanistic probes for structural studies with the arginine methyltransferase CARM1.

Authors:  Matthijs J van Haren; Nils Marechal; Nathalie Troffer-Charlier; Agostino Cianciulli; Gianluca Sbardella; Jean Cavarelli; Nathaniel I Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-22       Impact factor: 11.205

2.  Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.

Authors:  Giulia Iannelli; Ciro Milite; Nils Marechal; Vincent Cura; Luc Bonnefond; Nathalie Troffer-Charlier; Alessandra Feoli; Donatella Rescigno; Yalong Wang; Alessandra Cipriano; Monica Viviano; Mark T Bedford; Jean Cavarelli; Sabrina Castellano; Gianluca Sbardella
Journal:  J Med Chem       Date:  2022-04-28       Impact factor: 8.039

3.  Differential CARM1 Isoform Expression in Subcellular Compartments and among Malignant and Benign Breast Tumors.

Authors:  David Shlensky; Jennifer A Mirrielees; Zibo Zhao; Lu Wang; Aparna Mahajan; Menggang Yu; Nathan M Sherer; Lee G Wilke; Wei Xu
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

4.  Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma.

Authors:  Allison E Drew; Oscar Moradei; Suzanne L Jacques; Nathalie Rioux; Ann P Boriack-Sjodin; Christina Allain; Margaret Porter Scott; Lei Jin; Alejandra Raimondi; Jessica L Handler; Heidi M Ott; Ryan G Kruger; Michael T McCabe; Christopher Sneeringer; Thomas Riera; Gideon Shapiro; Nigel J Waters; Lorna H Mitchell; Kenneth W Duncan; Mikel P Moyer; Robert A Copeland; Jesse Smith; Richard Chesworth; Scott A Ribich
Journal:  Sci Rep       Date:  2017-12-21       Impact factor: 4.379

Review 5.  Protein arginine methylation/demethylation and cancer.

Authors:  Coralie Poulard; Laura Corbo; Muriel Le Romancer
Journal:  Oncotarget       Date:  2016-10-11

6.  Structural and biochemical evaluation of bisubstrate inhibitors of protein arginine N-methyltransferases PRMT1 and CARM1 (PRMT4).

Authors:  Emma A Gunnell; Alaa Al-Noori; Usama Muhsen; Clare C Davies; James Dowden; Ingrid Dreveny
Journal:  Biochem J       Date:  2020-02-28       Impact factor: 3.857

7.  CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas.

Authors:  Kylee J Veazey; Donghang Cheng; Kevin Lin; Oscar D Villarreal; Guozhen Gao; Mabel Perez-Oquendo; Hieu T Van; Sabrina A Stratton; Michael Green; Han Xu; Yue Lu; Mark T Bedford; Margarida Almeida Santos
Journal:  Leukemia       Date:  2020-06-24       Impact factor: 11.528

8.  CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis.

Authors:  Sarah M Greenblatt; Na Man; Pierre-Jacques Hamard; Takashi Asai; Daniel Karl; Concepcion Martinez; Daniel Bilbao; Vasileios Stathias; Anna M Jermakowicz; Stephanie Duffort; Madhavi Tadi; Ezra Blumenthal; Samantha Newman; Ly Vu; Ye Xu; Fan Liu; Stephan C Schurer; Michael T McCabe; Ryan G Kruger; Mingjiang Xu; Feng-Chun Yang; Daniel G Tenen; Justin Watts; Francisco Vega; Stephen D Nimer
Journal:  Cancer Cell       Date:  2018-06-11       Impact factor: 31.743

9.  A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor α-dependent transcriptional activation and breast carcinogenesis.

Authors:  Bing-Ling Peng; Wen-Juan Li; Jian-Cheng Ding; Yao-Hui He; Ting Ran; Bing-Lan Xie; Zi-Rui Wang; Hai-Feng Shen; Rong-Quan Xiao; Wei-Wei Gao; Tian-Yi Ye; Xiang Gao; Wen Liu
Journal:  Theranostics       Date:  2020-02-10       Impact factor: 11.556

10.  AMPK-ERK/CARM1 Signaling Pathways Affect Autophagy of Hepatic Cells in Samples of Liver Cancer Patients.

Authors:  Qiu-Fang Qin; Xiao-Jun Li; Yu-Sang Li; Wei Kevin Zhang; Gui-Hua Tian; Hong-Cai Shang; He-Bin Tang
Journal:  Front Oncol       Date:  2019-11-14       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.